NO324219B1 - Fenylpyridazin-forbindelser, medisiner og farmasoytiske preparater inneholdende disse samt anvendelse av disse for fremstilling av medikamenter for behandling av sykdom - Google Patents

Fenylpyridazin-forbindelser, medisiner og farmasoytiske preparater inneholdende disse samt anvendelse av disse for fremstilling av medikamenter for behandling av sykdom

Info

Publication number
NO324219B1
NO324219B1 NO20030097A NO20030097A NO324219B1 NO 324219 B1 NO324219 B1 NO 324219B1 NO 20030097 A NO20030097 A NO 20030097A NO 20030097 A NO20030097 A NO 20030097A NO 324219 B1 NO324219 B1 NO 324219B1
Authority
NO
Norway
Prior art keywords
group
treatment
medicaments
drugs
disease
Prior art date
Application number
NO20030097A
Other languages
English (en)
Other versions
NO20030097L (no
NO20030097D0 (no
Inventor
Hiromichi Shigyo
Masao Ohkuchi
Yoshinori Kyotani
Tomoyuki Koshi
Tadaaki Ohgiya
Takayuki Matsuda
Natsuyo Kumai
Kyoko Yasuoka
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of NO20030097L publication Critical patent/NO20030097L/no
Publication of NO20030097D0 publication Critical patent/NO20030097D0/no
Publication of NO324219B1 publication Critical patent/NO324219B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/12—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20030097A 2000-07-10 2003-01-09 Fenylpyridazin-forbindelser, medisiner og farmasoytiske preparater inneholdende disse samt anvendelse av disse for fremstilling av medikamenter for behandling av sykdom NO324219B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/612,953 US6664256B1 (en) 2000-07-10 2000-07-10 Phenylpyridazine compounds and medicines containing the same
PCT/JP2001/005904 WO2002004427A1 (fr) 2000-07-10 2001-07-06 Derives de phenylpyridazine et medicaments contenant ces derniers

Publications (3)

Publication Number Publication Date
NO20030097L NO20030097L (no) 2003-01-09
NO20030097D0 NO20030097D0 (no) 2003-01-09
NO324219B1 true NO324219B1 (no) 2007-09-10

Family

ID=24455274

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030097A NO324219B1 (no) 2000-07-10 2003-01-09 Fenylpyridazin-forbindelser, medisiner og farmasoytiske preparater inneholdende disse samt anvendelse av disse for fremstilling av medikamenter for behandling av sykdom

Country Status (15)

Country Link
US (1) US6664256B1 (no)
EP (1) EP1300399B1 (no)
JP (1) JP4915715B2 (no)
KR (1) KR100777623B1 (no)
CN (1) CN1272326C (no)
AT (1) ATE370735T1 (no)
AU (2) AU2001269474B2 (no)
CA (1) CA2413042A1 (no)
DE (1) DE60130119T2 (no)
HU (1) HUP0301230A3 (no)
NO (1) NO324219B1 (no)
NZ (1) NZ523242A (no)
RU (1) RU2269519C2 (no)
TW (1) TW593285B (no)
WO (1) WO2002004427A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2307111C (en) * 1997-11-19 2009-06-30 Kowa Co., Ltd. Novel pyridazine derivatives and drugs containing the same as the active ingredient
EP1431293B1 (en) * 2001-09-26 2011-06-08 Kowa Co., Ltd. Water-soluble phenylpyridazine derivatives and drugs containing the same
ES2355472T3 (es) 2002-05-22 2011-03-28 Amgen Inc. Derivados de aminopirimidina para su uso como ligandos del receptor vaniloide para el tratamiento del dolor.
TW200410945A (en) * 2002-08-08 2004-07-01 Amgen Inc Vanilloid receptor ligands and their use in treatments"
EP1688408A3 (en) * 2002-08-08 2007-08-22 Amgen, Inc Vanilloid receptor ligands and their use in treatments
NZ541064A (en) * 2003-03-07 2007-09-28 Kowa Co Benzofuran derivative
CA2518227A1 (en) * 2003-03-18 2004-09-30 Kowa Co., Ltd Water-soluble phenylpyridazine derivative and medicine containing the same
WO2005012259A1 (ja) * 2003-07-30 2005-02-10 Kowa Co., Ltd. オステオポンチン産生抑制方法
BRPI0414883A (pt) 2003-09-29 2006-12-12 Ethena Healthcare Inc composição, concentrado de composição, e, composições alcoólicas desinfetante e semelhante a gel
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
DE102004062775A1 (de) 2004-12-21 2006-06-29 Stockhausen Gmbh Alkoholischer Pumpschaum
KR101455554B1 (ko) 2005-03-07 2014-10-27 디이비 월드와이드 헬스케어 인코포레이티드 실리콘-기제 계면활성제를 갖는 고함량 알코올 폼 형성 조성물
TW200716594A (en) * 2005-04-18 2007-05-01 Neurogen Corp Substituted heteroaryl CB1 antagonists
WO2007123939A2 (en) * 2006-04-19 2007-11-01 Laboratoires Serono S.A. Novel arylamino n-heteraryls as mek inhibitors
US8580860B2 (en) * 2007-02-23 2013-11-12 Gojo Industries, Inc. Foamable alcoholic composition
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) * 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
TWI510241B (zh) 2010-02-18 2015-12-01 Vtv Therapeutice Llc 苯基－雜芳基衍生物及其使用方法
GB2497476B (en) * 2010-09-06 2018-01-10 Guangzhou Inst Biomed & Health Amide Compounds
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
WO2012111024A1 (en) 2011-02-18 2012-08-23 Suven Nishtaa Pharma Pvt Ltd Pharmaceutical compositions of dexlansoprazole
WO2021193897A1 (ja) * 2020-03-27 2021-09-30 アステラス製薬株式会社 置換ピリダジン化合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3840597A (en) 1971-02-24 1974-10-08 Riker Laboratories Inc Substituted 2-phenoxy alkane-sulfonanilides
US4092311A (en) * 1976-06-03 1978-05-30 American Cyanamid Company Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates
JPH0753725B2 (ja) 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
FI91062C (fi) 1988-12-28 1994-05-10 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisten naftaleenijohdannaisten valmistamiseksi
JPH06501926A (ja) * 1990-08-06 1994-03-03 藤沢薬品工業株式会社 複素環式化合物
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
EP0628550B1 (en) 1993-06-08 1998-02-25 Sanofi Pyridazines as interleukin-1beta converting enzyme inhibitors
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
CA2228050A1 (en) 1995-08-10 1997-02-20 Harold G. Selnick 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
JP2001514669A (ja) 1997-03-14 2001-09-11 メルク フロスト カナダ アンド カンパニー シクロオキシゲナーゼ−２阻害薬としてのピリダジノン類
CA2299300C (en) 1997-08-22 2007-04-17 Abbott Laboratories Arylpyridazinones as prostaglandin endoperoxide h synthase bisoynthesis inhibitors
ATE319691T1 (de) 1997-08-22 2006-03-15 Abbott Lab Prostaglandin endoperoxyde h synthase biosynthese inhibitoren
CA2307111C (en) 1997-11-19 2009-06-30 Kowa Co., Ltd. Novel pyridazine derivatives and drugs containing the same as the active ingredient
JP3999861B2 (ja) * 1997-11-19 2007-10-31 興和株式会社 新規ピリダジン誘導体及びこれを有効成分とする医薬
AU755421B2 (en) * 1997-12-19 2002-12-12 Amgen, Inc. Substituted pyridine and pyridazine compounds and their pharmaceutical use
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
TR200101765T2 (tr) 1998-10-27 2002-02-21 Abbott Laboratories Prostaglandin endoperoksit H sentaz biyosentez inhibitörleri
US6350744B1 (en) * 1998-11-20 2002-02-26 Merck & Co., Inc. Compounds having cytokine inhibitory activity
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity

Also Published As

Publication number Publication date
DE60130119D1 (de) 2007-10-04
WO2002004427A1 (fr) 2002-01-17
KR20030007948A (ko) 2003-01-23
JP4915715B2 (ja) 2012-04-11
NO20030097L (no) 2003-01-09
AU6947401A (en) 2002-01-21
ATE370735T1 (de) 2007-09-15
AU2001269474B2 (en) 2005-09-15
TW593285B (en) 2004-06-21
US6664256B1 (en) 2003-12-16
EP1300399A1 (en) 2003-04-09
EP1300399B1 (en) 2007-08-22
RU2269519C2 (ru) 2006-02-10
CA2413042A1 (en) 2002-01-17
EP1300399A4 (en) 2004-02-11
DE60130119T2 (de) 2007-12-13
NZ523242A (en) 2004-10-29
CN1272326C (zh) 2006-08-30
HUP0301230A2 (hu) 2003-12-29
CN1440392A (zh) 2003-09-03
KR100777623B1 (ko) 2007-11-27
HUP0301230A3 (en) 2004-03-29
NO20030097D0 (no) 2003-01-09

Similar Documents

Publication Publication Date Title
NO324219B1 (no) Fenylpyridazin-forbindelser, medisiner og farmasoytiske preparater inneholdende disse samt anvendelse av disse for fremstilling av medikamenter for behandling av sykdom
DE69829875D1 (de) Piperazin-verbindungen und ihre medizinische verwendung
HUP0401889A2 (hu) 1,8-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények
DK1213296T3 (da) Glucopyranosyloxpyrazolderivater, lægemidler indeholdende samme samt mellemprodukter til fremstilling heraf
HUP0302167A2 (hu) Metabotropikus glutamát receptor antagonista hatású kinolinszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
DE69426331D1 (de) Arzneimittel gegen nervöse erkrankungen
MY145408A (en) Dihydropyrazolopyrimidinone derivatives
MXPA04001507A (es) Derivado de tetrazoiloxima y producto quimico agricola que contiene el mismo como ingrediente activo.
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
HUP0002272A2 (hu) Piperazinszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
DE3869907D1 (de) Chinolincarbonsaeure-derivate.
WO2000064874A3 (en) Heterosubstituted pyridine derivatives as pde 4 inhibitors
EP1142881A4 (en) POLY (ADP-RIBOSE) POLYMERASE INHIBITORS CONSISTING OF PYRIMIDINE DERIVATIVES
AU8811401A (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
CY1112057T1 (el) Θεραπευτικος παραγων για διαταραχη επαρκειας τροφης στο στομαχι
NO20014099D0 (no) Pyridazin-3-on derivater og medikamenter inneholdende disse
NO20022123L (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
ATE398614T1 (de) Triazolverbindungen und ihre therapeutische verwendung
BR0308935A (pt) Inibidor de fosfodiesterase iv contendo derivado de piridilacrilamida
DE69925160D1 (de) Arylpiperidin- und aryl-1,2,5,6-tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität
PT1140925E (pt) 3,4-di-hidro-2h-benzo¬1,4|oxazinil-metil-¬3-(1h-indol-3il)-alquil|-aminas
HUP0204579A2 (hu) Pirrolopiridazinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO20063353L (no) 1,2,3,4-tetrahydroisokinolinderivater, fremgangsmate for fremstilling derav og anvendelser derav
IT1247137B (it) Derivati dell'acido 5-fenil-1h-pirazol-4-propionico, loro preparazione e loro impiego come medicamenti

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees